PH-ILD Program
Pulmonary Hypertension Associated with Interstitial Lung Disease
Phase 2aCompleted
Key Facts
Indication
Pulmonary Hypertension Associated with Interstitial Lung Disease
Phase
Phase 2a
Status
Completed
Company
About Insmed
Insmed is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform lives of patients facing serious diseases. The company has achieved commercial success with approved therapies in the US and EU, while advancing multiple programs through clinical development. Insmed has been consistently recognized as Science magazine's #1 Top Biopharma Employer for five consecutive years and maintains a culture of collaboration and innovation across 9 corporate offices worldwide.
View full company profileTherapeutic Areas
Other Pulmonary Hypertension Associated with Interstitial Lung Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| Mosliciguat | Roivant Sciences | Proof of Concept |